Form 4: Acadia Pharmaceuticals Executive James Kihara Reports Stock Transactions

Principal Accounting Officer James Kihara of Acadia Pharmaceuticals reports the vesting and sale of restricted stock units to cover tax obligations.

Summary

• James Kihara, Principal Accounting Officer of Acadia Pharmaceuticals, reported transactions involving the company's common stock.
• On May 1, 2025, 2,596 restricted stock units vested and were converted into common stock.
• Simultaneously, 2,596 shares were disposed of to cover withholding taxes.
• On May 2, 2025, Kihara sold 1,327 shares of common stock at a price of $14.6 per share.
• Following these transactions, Kihara directly owns 23,526 shares of Acadia Pharmaceuticals common stock and 5,192 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of company executives.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by an executive, but the impact is likely minimal given the relatively small number of shares involved.

Key Dates

Keywords

Acadia Pharmaceuticals, James Kihara, stock transaction, restricted stock units, Form 4, insider trading, common stock, vesting, tax withholding